The Talent Wars: Why People, Not Capital, Will Define the Future of AI Drug Discovery
The AI drug discovery sector is in the midst of a profound transformation. After years of promise fueled by speculative funding, 2025 has marked a decisive flight to quality. Capital is no longer the primary constraint; it is abundant and consolidating. The true race is now for the three strategic assets that cannot be easily […]